Published in Drug Metab Dispos on February 28, 2006
Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse. J Pharmacol Exp Ther (2007) 1.57
Development of active and passive human vaccines to treat methamphetamine addiction. Hum Vaccin (2009) 1.27
Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (+)-methamphetamine addiction. CNS Neurol Disord Drug Targets (2011) 1.21
The effect of a chimeric human/murine anti-cocaine monoclonal antibody on cocaine self-administration in rats. J Pharmacol Exp Ther (2008) 1.12
Anti-(+)-methamphetamine monoclonal antibody antagonists designed to prevent the progression of human diseases of addiction. Clin Pharmacol Ther (2010) 1.10
Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use. MAbs (2013) 0.97
An antidote for acute cocaine toxicity. Mol Pharm (2012) 0.95
Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food. Vaccine (2013) 0.95
Immunopharmacotherapeutic manifolds and modulation of cocaine overdose. Pharmacol Biochem Behav (2011) 0.93
Combined active and passive immunization against nicotine: minimizing monoclonal antibody requirements using a target antibody concentration strategy. Int Immunopharmacol (2011) 0.91
Pharmacological effects of two anti-methamphetamine monoclonal antibodies. Supporting data for lead candidate selection for clinical development. Hum Vaccin Immunother (2014) 0.86
Effects of active anti-methamphetamine vaccination on intravenous self-administration in rats. Drug Alcohol Depend (2015) 0.85
Engineering and characterization of a mouse/human chimeric anti-phencyclidine monoclonal antibody. Int Immunopharmacol (2007) 0.84
The fate and function of therapeutic antiaddiction monoclonal antibodies across the reproductive cycle of rats. J Pharmacol Exp Ther (2010) 0.81
Immunogenicity of individual vaccine components in a bivalent nicotine vaccine differ according to vaccine formulation and administration conditions. PLoS One (2013) 0.80
Chronic anti-phencyclidine monoclonal antibody therapy decreases phencyclidine-induced in utero fetal mortality in pregnant rats. Int Immunopharmacol (2011) 0.77
Immunotherapy for the treatment of drug abuse. Pharmacol Ther (2005) 2.11
Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol Sci (2010) 1.91
Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse. J Pharmacol Exp Ther (2007) 1.57
Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther (2002) 1.53
Cerebral blood flow velocities in extremely low birth weight infants with hypotension and infants with normal blood pressure. J Pediatr (2009) 1.53
Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats. Eur J Pharmacol (2005) 1.49
Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats. Eur J Pharmacol (2003) 1.49
Use of anti-(+)-methamphetamine monoclonal antibody to significantly alter (+)-methamphetamine and (+)-amphetamine disposition in rats. Drug Metab Dispos (2003) 1.49
Comparisons of vegetarian and beef-containing diets on hematological indexes and iron stores during a period of resistive training in older men. J Am Diet Assoc (2003) 1.43
The effects of massage therapy to induce sleep in infants born preterm. Pediatr Phys Ther (2014) 1.40
Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats. Int Immunopharmacol (2006) 1.39
The uremic toxin 3-indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor. Biochemistry (2010) 1.32
Functional and biological determinants affecting the duration of action and efficacy of anti-(+)-methamphetamine monoclonal antibodies in rats. Vaccine (2009) 1.31
In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther (2005) 1.31
Development of active and passive human vaccines to treat methamphetamine addiction. Hum Vaccin (2009) 1.27
The synthesis of haptens and their use for the development of monoclonal antibodies for treating methamphetamine abuse. J Med Chem (2009) 1.24
In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther (2004) 1.23
Sex- and dose-dependency in the pharmacokinetics and pharmacodynamics of (+)-methamphetamine and its metabolite (+)-amphetamine in rats. Toxicol Appl Pharmacol (2005) 1.22
Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging (2005) 1.22
Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (+)-methamphetamine addiction. CNS Neurol Disord Drug Targets (2011) 1.21
Development and preclinical testing of a high-affinity single-chain antibody against (+)-methamphetamine. J Pharmacol Exp Ther (2008) 1.20
Sex differences in (+)-amphetamine- and (+)-methamphetamine-induced behavioral response in male and female Sprague-Dawley rats. Pharmacol Biochem Behav (2007) 1.18
Pancreatitis: prevalence and risk factors among male veterans in a detoxification program. Pancreas (2007) 1.17
The effects of hypercapnia on cerebral autoregulation in ventilated very low birth weight infants. Pediatr Res (2005) 1.16
Cost-effectiveness analysis of a rural telemedicine collaborative care intervention for depression. Arch Gen Psychiatry (2010) 1.11
Synthesis of mercapto-(+)-methamphetamine haptens and their use for obtaining improved epitope density on (+)-methamphetamine conjugate vaccines. J Med Chem (2011) 1.10
(+)-Methamphetamine-induced spontaneous behavior in rats depends on route of (+)METH administration. Pharmacol Biochem Behav (2004) 1.06
Optimal learning environments from the perspective of resident physicians and associations with accreditation length. Acad Med (2007) 1.06
Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J Clin Pharmacol (2006) 1.04
Monoclonal antibody form and function: manufacturing the right antibodies for treating drug abuse. AAPS J (2006) 1.03
Quantitative determination of total methamphetamine and active metabolites in rat tissue by liquid chromatography with tandem mass spectrometric detection. AAPS J (2006) 1.03
Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. Mol Nutr Food Res (2008) 1.02
Treatment of adverse effects of excessive phencyclidine exposure in rats with a minimal dose of monoclonal antibody. J Pharmacol Exp Ther (2003) 1.02
Maternal high fat diet during the perinatal period alters mesocorticolimbic dopamine in the adult rat offspring: reduction in the behavioral responses to repeated amphetamine administration. Psychopharmacology (Berl) (2007) 1.02
Comparing the sensitivity of generic effectiveness measures with symptom improvement in persons with schizophrenia. Med Care (2003) 1.01
One size fits some: the impact of patient treatment attitudes on the cost-effectiveness of a depression primary-care intervention. Psychol Med (2005) 1.01
Multi-species analyses of direct activators of the constitutive androstane receptor. Toxicol Sci (2011) 1.00
First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers. MAbs (2014) 0.99
Surfactant administration acutely affects cerebral and systemic hemodynamics and gas exchange in very-low-birth-weight infants. J Pediatr (2004) 0.99
Gamma band activity in the developing parafascicular nucleus. J Neurophysiol (2011) 0.99
Cost-effectiveness of a primary care depression intervention. J Gen Intern Med (2003) 0.99
Selective phthalate activation of naturally occurring human constitutive androstane receptor splice variants and the pregnane X receptor. Toxicol Sci (2011) 0.97
How well do automated performance measures assess guideline implementation for new-onset depression in the Veterans Health Administration? Jt Comm J Qual Saf (2003) 0.97
Open-label pilot study of modafinil for methamphetamine dependence. J Clin Psychopharmacol (2009) 0.96
Cholinergic and glutamatergic agonists induce gamma frequency activity in dorsal subcoeruleus nucleus neurons. Am J Physiol Cell Physiol (2011) 0.96
Crystal structures of a therapeutic single chain antibody in complex with two drugs of abuse-Methamphetamine and 3,4-methylenedioxymethamphetamine. Protein Sci (2009) 0.96
Transpleural subclavian central venous catheter placement in a child with scoliosis discovered during a thoracotomy. J Clin Anesth (2003) 0.96
Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food. Vaccine (2013) 0.95
A single dose of monoclonal anti-phencyclidine IgG offers long-term reductions in phencyclidine behavioral effects in rats. J Pharmacol Exp Ther (2002) 0.94
Depression-free day to utility-weighted score: is it valid? Med Care (2007) 0.91
Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos (2005) 0.91
Clinical practice variations in prescribing antipsychotics for patients with schizophrenia. Am J Med Qual (2003) 0.90
Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms. Addiction (2011) 0.89
Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol Nutr Food Res (2008) 0.89
Pharmacological effects of two anti-methamphetamine monoclonal antibodies. Supporting data for lead candidate selection for clinical development. Hum Vaccin Immunother (2014) 0.86
Service utilization and outcomes in medically ill veterans with posttraumatic stress and depressive disorders. J Trauma Stress (2003) 0.85
Designing immunotherapies to thwart drug abuse. Mol Interv (2009) 0.85
Engineering and characterization of a mouse/human chimeric anti-phencyclidine monoclonal antibody. Int Immunopharmacol (2007) 0.84
Evidence for validity of a survey to measure the learning environment for professionalism. Med Teach (2011) 0.84
Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos (2006) 0.83
Does the learning deficit observed under an incremental repeated acquisition schedule of reinforcement in Ts65Dn mice, a model for Down syndrome, change as they age? Behav Brain Res (2009) 0.82
Olivary climbing fiber alterations in PN40 rat cerebellum following postnatal ethanol exposure. Brain Res (2011) 0.82
Effects of leptin on pedunculopontine nucleus (PPN) neurons. J Neural Transm (Vienna) (2012) 0.81
Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure. Exp Clin Psychopharmacol (2013) 0.81
Effect of pentobarbital, d-amphetamine, and nicotine on two models of sustained attention in pigeons. Psychopharmacology (Berl) (2002) 0.81
The fate and function of therapeutic antiaddiction monoclonal antibodies across the reproductive cycle of rats. J Pharmacol Exp Ther (2010) 0.81
Long-term deficits of preterm birth: evidence for arousal and attentional disturbances. Clin Neurophysiol (2008) 0.80
Cost-effectiveness of a primary care intervention for depressed females. J Affect Disord (2003) 0.80
Vulnerability to (+)-methamphetamine effects and the relationship to drug disposition in pregnant rats during chronic infusion. Toxicol Sci (2009) 0.80
Test-retest reliability of in situ unaided thresholds in adults. Am J Audiol (2006) 0.80
The effect of a forensic fellowship program on general psychiatry residents' in-training examination outcomes. J Am Acad Psychiatry Law (2010) 0.79
Gestation time-dependent pharmacokinetics of intravenous (+)-methamphetamine in rats. Drug Metab Dispos (2011) 0.79